By Michael Dabaie

 

AstraZeneca and Merck & Co. said Lynparza demonstrated a long-term progression-free survival benefit versus placebo.

The companies said Lynparza demonstrated a long-term progression-free survival benefit versus placebo as a first-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who had a complete or partial response following platinum-based chemotherapy.

Five-year follow-up data from the Phase III SOLO-1 trial showed Lynparza reduced the risk of disease progression or death by 67% and improved progression-free survival to a median of 56.0 months versus 13.8 months for placebo.

At five years, 48.3% of patients treated with Lynparza remained free from disease progression versus 20.5% on placebo.

The median duration of treatment with Lynparza was 24.6 months, versus 13.9 months with placebo, the companies said.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

September 18, 2020 10:20 ET (14:20 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2020 to Oct 2020 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Oct 2019 to Oct 2020 Click Here for more Merck Charts.